FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 20, 2020 at 11:22 AM.

  1. #1 cafead, Feb 20, 2020 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Roche (OTC: RHHBY) announced on Wednesday that the U.S. Food and Drug Administration had accepted its supplemental Biologics License Application for the cancer drug Tecentriq. In addition, the FDA also granted a Priority Review to the drug for use in patients with non-squamous and squamous non-small cell lung cancers.

    article source
     
    Quote

Reply to Thread